>
Aimmune Therapeutics Inc logo

AIMT - Aimmune Therapeutics Inc Share Price

$34.49 0.0  0.0%

Last Trade - 12/10/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £416k
Position in Universe th / 6850
Bullish
Bearish
Unlock AIMT Revenue
Momentum
Relative Strength (%)
1m -5.32%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 8.96 103.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AimmuneTherapeutics Inc revenues increased from $0K to $575K. Netloss increased 33% to $155.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsEmployee-related costs increase of 83% to $36.3M (expense),General and Administrative - other increase of 50% to$36.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AIMT Revenue Unlock AIMT Revenue

Net Income

AIMT Net Income Unlock AIMT Revenue

Normalised EPS

AIMT Normalised EPS Unlock AIMT Revenue

PE Ratio Range

AIMT PE Ratio Range Unlock AIMT Revenue

Dividend Yield Range

AIMT Dividend Yield Range Unlock AIMT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AIMT EPS Forecasts Unlock AIMT Revenue
Profile Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 24, 2011
Public Since August 6, 2015
No. of Shareholders: 15
No. of Employees: 339
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 65,450,142
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AIMT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AIMT
Upcoming Events for AIMT
Frequently Asked Questions for Aimmune Therapeutics Inc
What is the Aimmune Therapeutics Inc share price?

As of 12/10/20, shares in Aimmune Therapeutics Inc are trading at $34.49, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Aimmune Therapeutics Inc share price performed this year?

Shares in Aimmune Therapeutics Inc are currently trading at $34.49 and the price has moved by 40.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aimmune Therapeutics Inc price has moved by -3.16% over the past year.

What are the analyst and broker recommendations for Aimmune Therapeutics Inc?

Of the analysts with advisory recommendations for Aimmune Therapeutics Inc, there are there are currently 0 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aimmune Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Aimmune Therapeutics Inc next release its financial results?

Aimmune Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Aimmune Therapeutics Inc dividend yield?

Aimmune Therapeutics Inc does not currently pay a dividend.

Does Aimmune Therapeutics Inc pay a dividend?

Aimmune Therapeutics Inc does not currently pay a dividend.

When does Aimmune Therapeutics Inc next pay dividends?

Aimmune Therapeutics Inc does not currently pay a dividend.

How do I buy Aimmune Therapeutics Inc shares?

To buy shares in Aimmune Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aimmune Therapeutics Inc?

Shares in Aimmune Therapeutics Inc are currently trading at $34.49, giving the company a market capitalisation of £n/a.

Where are Aimmune Therapeutics Inc shares listed? Where are Aimmune Therapeutics Inc shares listed?

Here are the trading details for Aimmune Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AIMT
What kind of share is Aimmune Therapeutics Inc?

We were not able to load our ranking data for Aimmune Therapeutics Inc

Is there a Aimmune Therapeutics Inc share price forecast 2021?

We were not able to load any forecast data for Aimmune Therapeutics Inc.

How can I tell whether the Aimmune Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aimmune Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 81.56%. At the current price of $34.49, shares in Aimmune Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aimmune Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Aimmune Therapeutics Inc.

Who are the key directors of Aimmune Therapeutics Inc?

We were unable to find the directors for Aimmune Therapeutics Inc.

Who are the major shareholders of Aimmune Therapeutics Inc?

Here are the top five shareholders of Aimmune Therapeutics Inc based on the size of their shareholding:

Nestle Health Science US Holdings, Inc. Corporation
Percentage owned: 19.46% (12.7m shares)
Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 9.19% (6.01m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 8.06% (5.27m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.42% (4.20m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 5.69% (3.73m shares)
Similar to AIMT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.